/Quest%20Diagnostics%2C%20Inc_%20logo%20on%20building-by%20Tada%20Images%20via%20Shutterstock.jpg)
Quest Diagnostics Incorporated (DGX), headquartered in Secaucus, New Jersey, provides diagnostic testing and services. Valued at $17.2 billion by market cap, the company operates a national network of full-service laboratories, rapid response laboratories, and patient service centers. DGX offers esoteric, routine medical, drugs of abuse, and non-hospital-based anatomic pathology testing services. The leading provider of diagnostic testing and services is expected to announce its fiscal fourth-quarter earnings for 2024 before the market opens on Thursday, Jan. 30.
Ahead of the event, analysts expect DGX to report a profit of $2.19 per share on a diluted basis, up 1.9% from $2.15 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports.
